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Abstract
Prescription opioid abuse is an increasing public health concern in the USA. A vaccine comprising a hapten (OXY)
conjugated to the carrier protein keyhole limpet hemocyanin (OXY-KLH) has been shown to attenuate the antinociceptive
effects of oxycodone. Here, the vaccine’s ability to prevent acquisition of intravenous (i.v.) oxycodone self-administration
was studied in rats. Effects of vaccination on oxycodone-induced changes in the expression of several genes within the
mesolimbic system, which are regulated by chronic opiate use, were also examined. Vaccination with OXY-KLH reduced the
proportion of rats acquiring i.v. self-administration of oxycodone under a fixed ratio (FR) 3 schedule of reinforcement
compared to control rats immunized with the unconjugated KLH carrier protein. Vaccination significantly reduced the mean
number of infusions at FR3, total number of infusions, and total oxycodone intake during the entire protocol. Compared to
oxycodone self-administering control rats immunized with the carrier alone, rats vaccinated with the OXY-KLH immunogen
showed increased levels of adenylate cyclase 5 (Adcy5) and decreased levels of early growth response protein 2 (Egr2) and
the early immediate gene c-Fos in the striatum. These data suggest that vaccination with OXY-KLH can attenuate the
reinforcing effects of oxycodone at a clinically-relevant exposure level. Analysis of mRNA expression identified some
addiction-relevant markers that may be of interest in understanding oxycodone effects or the protection provided by
vaccination.
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Introduction
Current pharmacotherapies for treatment of opioid addiction
are effective, but show side effects and limitations. New strategies
to meet the therapeutic challenge of treating opioid addiction are
needed [1]. Active immunization with conjugate vaccines has been
studied as a complementary option for the treatment of drug
addiction [2].
Early studies of morphine conjugate vaccines showed that
immunization attenuated heroin self-administration in non-human
primates, decreased morphine brain distribution and attenuated
morphine analgesia in mice and rats [3–5]. Development of
immunotherapy strategies for treatment of opioid addiction was
abandoned in the 70’s, presumably because of Food and Drug
Administration (FDA) approval of methadone replacement ther-
apy, which quickly became the main form of treatment for opioid
addiction [6]. More recent reports have shown that immunization
with heroin or morphine conjugate vaccines, containing haptens
based on morphine or 6-acetlymorphine, decreases brain distri-
bution of the primary active heroin metabolite 6-acetylmorphine
and attenuates heroin and morphine self-administration in rats [7–
12]. These vaccines have not yet reached clinical trials.
Prescription opioids such as oxycodone and hydrocodone have
high abuse liability, are widely prescribed as analgesics, and are
readily accessible to teens and young adults, all of which are
factors that have led to their increased abuse [13]. To address
prescription opioid abuse, our laboratory developed a vaccine
(OXY-KLH) that elicits the production of high titers of serum
antibodies that bind oxycodone and hydrocodone in serum,
prevents early distribution of clinically-relevant doses of oxyco-
done and hydrocodone to brain, and blocks oxycodone and
hydrocodone antinociception in mice and rats [14–17]. The
purpose of the present study was to test whether vaccination with
OXY-KLH would prevent the acquisition of oxycodone self-
administration in rats, an addiction-relevant behavior, in order to
assess its efficacy in a pre-clinical model of prescription opioid
abuse. Oxycodone self-administration has been previously char-
acterized in animal models of addiction and reward [18–22];
however no studies have yet addressed the effects of vaccination
against oxycodone in these models.
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to characterize the extent to which vaccination with OXY-KLH
mitigates some of the neural changes induced by repeated
oxycodone exposure. For instance it has been shown that
oxycodone self-administration increases striatal dopamine levels
[22]. A number of genes have been identified in brain regions
implicated in mediating addiction, most notably the striatum,
which are up- or down-regulated in response to repeated or
persistent opioid exposure. Changes in brain gene expression have
been reported after repeated experimenter-administered oxyco-
done in rats [23,24] or after oxycodone self-administration in mice
[20,21]. These more recent studies showed that oxycodone self-
administration alters gene expression in various neurotransmitter
systems in the mouse dorsal striatum [20,21].
Vaccination with OXY-KLH reduces brain concentrations of
oxycodone in rats after a single oxycodone dose that elicits near
maximal antinociception in the hot plate test [14]. It is not clear if
this acute reduction in oxycodone distribution to the brain is
sufficient to protect against repeated drug-induced changes in gene
expression that may be involved in mediating reward and
addiction. Evaluating gene expression during the acquisition of
oxycodone self-administration in vaccinated rats affords an
opportunity to address this question in a behaviorally relevant
context.
In the current study, we investigated the effects of vaccination
on the acquisition of oxycodone self-administration in rats. For
exploratory purposes, after completion of the oxycodone self-
administration study, we also evaluated the effects of vaccination
on mRNA expression of opioid receptors and their downstream
effectors in the nucleus accumbens (NAc) and caudate putamen




All studies were approved by the Minneapolis Medical
Foundation Care and Use Committee (protocol #08–10). All
animals were euthanized by CO2 inhalation using AAALAC
approved chambers, and efforts were made to minimize suffering
and discomfort.
2.2. Animals
All animal studies were approved by the Minneapolis Medical
Research Foundation Institutional Animal Care and Use Com-
mittee. Male Holtzman rats (300–324 grams at arrival) were
purchased from Harlan (Indianapolis, IN), and housed in a
temperature- and humidity-controlled colony room on a 12/
12 hours dark/light inverted schedule. Rats had unlimited access
to water, but were food restricted to 18 grams per day of standard
rat chow.
2.3 Drugs and reagents
Oxycodone was obtained from Sigma (St. Louis, MO) and doses
are expressed as the weight of the base.
2.4 Hapten synthesis and conjugation to carrier protein
An oxycodone hapten containing a tetraglycine linker at the C6
position (OXY) was first synthesized and then conjugated to
chicken ovalbumin (OVA) for ELISA assays or to the keyhole
limpet hemocyanin (KLH) carrier protein for vaccination studies
as previously described [14,15].
2.5 Serum antibody titers and concentrations
ELISA 96-well plates were coated with OXY-OVA conjugate
or unconjugated OVA control in carbonate buffer and blocked
with 1% gelatin. Primary antibodies were incubated with goat
anti-rat IgG antibodies to measure oxycodone-specific serum IgG
antibody titers, as described previously [15]. Rat oxycodone-
specific serum IgG concentrations were measured by ELISA using
a standard curve constructed using commercially available murine
monoclonal anti-oxycodone IgG (Qed Biosciences, San Diego,
CA), as previously described for anti-morphine IgG concentrations
[25].
2.6 Vaccination
Rats received the OXY-KLH conjugate vaccine or a control
vaccination consisting of the unconjugated KLH carrier protein
alone (n=12 each group). Rats were immunized i.p. with either
100 mg of each immunogen on days 0, 21, 42 and 63 using
Freund’s Complete Adjuvant for the first vaccination and Freund’s
Incomplete Adjuvant for all subsequent boosts as previously
described [15]. A week after the last immunization, tail vein blood
samples were collected to analyze oxycodone-specific serum
antibody titers and concentrations by ELISA. Rats were then
implanted with jugular vein indwelling catheters as previously
described [26].
2.7 Apparatus
Sixteen identical operant conditioning chambers (Med Associ-
ates, St. Albans, VT) were used for oxycodone self-administration.
Each chamber was equipped with two response levers, a white cue
light above each lever, a receptacle between the levers for delivery
of food pellets (not used), and a house light for ambient
illumination of the chamber. Each chamber was also equipped
with a counterbalanced fluid swivel and tether, and an infusion
pump (Model PHS-100, Med Associates, St. Albans, VT) that
when activated delivered an infusion with a volume of 0.1 ml/kg
in approximately 0.8 sec. Operation of apparatus and recording of
data was controlled by MED-PC software and interfacing (Med-
Associates, St. Albans, VT).
2.8 Oxycodone i.v. self-administration studies
A week after surgery, rats were trained to respond under a fixed-
ratio (FR) 1 schedule in which each press of an active lever
produced an infusion of 0.06 mg/kg i.v.. Sessions began with onset
of the house light to signal availability of drug. Each infusion was
signaled by offset of the houselight and onset of the cue light over
the active lever during the infusion and a subsequent 6-sec
timeout, during which responses were recorded but had no
programmed consequence. Following the timeout, the cue light
extinguished and the house light was illuminated to signal
availability of the next unit dose. The training dose was chosen
based on previous studies showing this dose produces reinforcing
effects similar to heroin in rats [18]. Presses of the other (inactive)
lever were recorded but had no programmed consequence. After
ten sessions under the FR1 schedule, the FR value was increased
to FR2 and FR3 for five sessions each. Rats were considered to
have acquired self-administration if they earned at least 10
infusions per session and exhibited an active:inactive lever press
ratio of at least 2:1 during the last three sessions at FR3. Sessions
were 120 minutes in duration and ran five days per week.
2.9 Brain collection
At 24 hours after the last oxycodone self-administration session,
rats were rendered unconscious using CO2 chambers. Rats were
Vaccine Efficacy on Oxycodone Self-Administration and Brain mRNA
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dipped in isopentane kept in dry ice, wrapped in aluminum foil
and frozen at 280uC prior to gene expression analysis.
2.10 Quantitative real-time reverse transcriptase
polymerase chain reaction (qRT-PCR)
In this study, we analyzed mRNA expression of dynorphin,
kappa opioid receptor (KOR), Gai1, RGS9a, adenylate cyclase 5
(Adcy5), early growth response protein 2 (Egr2) and the early
immediate gene c-Fos, which were found altered after chronic
opioid administration in rats [27,28].
Frozen brains (280uC) were coronally sectioned on a cryostat
(HM 505 E; Microm, Walldorf, Germany) until the rostral nucleus
accumbens (NAc) and dorsal striatum (DStr) were exposed
(Bregma 2.20 mm). Bilateral tissue punches 1 mm in length were
taken of the NAc (diameter: 1 mm) and CPu (diameter: 2 mm)
and placed in Eppendorf tubes kept on dry ice. RNA was
extracted using PureLink RNA Mini Kit (Invitrogen) and
quantified using a Nanodrop 2000 (Thermo Scientific). Total
RNA (0.5 mg) was used to synthesize cDNA using iScript cDNA
Synthesis Kit (BioRad) in a ThermoHybaid iCycler (Thermo
Scientific). Primers specific for dynorphin (Dyn; Forward primer:
CGCAAATACCCCAAGAGGAG, Reverse Primer: GCAG-
GAAGCCCCCATAGC; product size, 109 bp), kappa opioid
receptor (KOR; Forward primer: CTCCCAGTGCTTGCC-
TACTC, Reverse Primer: AGATGTTGGTTGCGGTCTTC;
product size, 240 bp), adenylate cyclase 5 (Adcy5; Forward
primer: CCTCAACGACTCCACCTATG, Reverse primer:
AATGACCCCAGCCACTACAG; product size, 166 bp), Gai1
(Forward primer: TTTGGAGACGCTGCTCGTGCG, Reverse
primer: GTACGCCGCCGAATCGTTCA; product size,
180 bp), Gai2 (Forward primer: GATGATCGACAA-
GAACCTGCGGG, Reverse Primer: CAGGTTGCC-
CATGGCTTTGACG; product size, 223 bp), regulator of G-
protein signaling 9 (Rgs9; Forward primer: AACAGCTGCC-
CAGGCTGAAACC, Reverse primer: TTGAGAG-
CAAGTGTGCCCCAGG; product size, 255 bp), Fos (Fos;
Forward primer: CGGGAGTGGTGAAGACCATGTCAGG,
Reverse primer: TCCGCTTGGAGCGTATCTGTCAGC;
product size, 178 bp), early growth response 2 (Egr2; Forward
primer: TCCCCAATGGTGAACTGGGAGG, Reverse primer:
AGATGGGAGCGAAGCTACTCGG; product size, 132 bp),
tubulin, alpha 1A (Tuba1a; Forward primer: AGAAGCAA-
CACCTCCTCCTCGC; Reverse primer: AGGCTGGATGC-
CATGTTCCAGG; product size, 154 bp), integral membrane
protein 2B (Itm2B; Forward primer: CATCCTGGGAGGAG-
CATACC; Reverse primer: TCCGCAAACTCTGGTACAGG;
product size, 213 bp), and general transcription factor 2B (Gtf2B;
Forward primer: TGCGATAGCTTCTGCTTGTC; Reverse
primer: TCAGATCCACGCTCGTCTC; product size, 155 bp)
genes were designed using NCBI Primer-BLAST (http://www.
ncbi.nlm.nih.gov/tools/primer-blast/) and purchased from Inte-
grated DNA Technologies (Coralville, Iowa). Melt curve analysis
and polyacrylamide gel electrophoresis confirmed the specificity of
the primers.
A Q-PCR kit (iQ SybrGreen Supermix, BioRad) was used. The
qRT-PCR reaction was carried out using iQ SybrGreen Supermix
(BioRad) on a MyiQ Single Color Real-Time PCR Detection
System (BioRad) in a volume of 20 ml, with 2 ml of 3 mM forward
and reverse primers and 4 ml cDNA sample diluted 1:10. PCR
cycling conditions were 95uC for 5 min; 40 cycles at 94uC for 15 s,
60uC for 15 s, 72uC for 15 s. Data were collected at read
temperatures of 83–88uC for 15 s depending on amplicon melt
temperatures. Standard dilution curves were generated for each
primer set by serially diluting (1.00, 0.25, 0.0625, and 0.0156-fold)
a master cDNA stock comprising an equal mix of cDNA from all
treatment groups for a given brain region. The log10 of the dilution
values was plotted against the threshold cycle values to generate
standard curves. MyiQ Optical System Software (BioRad) was
used to analyze the data. Samples containing no cDNA template
and samples from cDNA synthesis reactions that contained no
reverse transcriptase (no RT) were run as controls for contami-
nation and amplification of genomic DNA, respectively. Reported
values were normalized to the average values of the internal
standards Tbp, Gtf2B, and Itm2B for each sample. Data are
expressed as mean relative levels of the gene of interest/internal
standards mRNA6SEM.
2.11 Statistical analysis
Mean daily infusions and responses on the active and inactive
levers were analyzed via two-way ANOVA with treatment as a
non-repeated factor and day as a repeated factor. Post-hoc
comparisons between groups were done using unpaired t-tests and
the False Discovery Rate (FDR), procedure with the FDR=5%
[29]. Mean infusions at FR3 (last three sessions), total infusions
and total oxycodone intake were compared between vaccinated
and control groups using unpaired t-tests, using Welch’s correction
where appropriate. The proportion of rats that met acquisition
criteria was compared between groups using a Chi-square test.
Quantitative RT-PCR data from each brain region were analyzed
with two-way ANOVA, with treatment as a non-repeated factor
and gene as a repeated factor. Significant effects between the
OXY-KLH vaccine and the unconjugated KLH control groups
were followed by Fisher’s Least Significant Difference (LSD) post-
hoc tests.
Results
3.1 Vaccination with OXY-KLH attenuates acquisition of
oxycodone i.v. self-administration
Vaccination with OXY-KLH resulted in oxycodone-specific
serum IgG antibody concentrations of 450665 mg/ml (mean6-
SEM), which are consistent with antibody concentrations previ-
ously observed in rats vaccinated with a heroin vaccine containing
an identical linker and KLH as carrier [10,25]. Compared to
control rats immunized with the unconjugated KLH, vaccination
with OXY-KLH reduced acquisition of oxycodone self-adminis-
tration by lowering active lever pressing, number of infusions per
session, overall oxycodone intake and also reduced the proportion
of rats meeting acquisition criteria.
Figure 1 shows the mean number of infusions earned (left panel)
and mean number of responses on the active and inactive levers
(right panel) per session. Table 1 shows a summary of the findings
for antibody titers and other measures of oxycodone self-
administration. Analysis of response rate data showed significant
main effects of treatment (F(1,16)=6.127, p,0.05) and day (F(19,
304)=8.125, p,0.0001), and a significant treatment x day
interaction (F(19, 304)=4.409, p,0.0001). Compared to KLH
controls, OXY-KLH vaccinated rats exhibited significantly lower
rates of active lever pressing overall. Analysis of infusion data
showed significant main effects of treatment (F(1,16)=6.616, p,
0.05) and day (F(19, 304)=2.791, p,0.001), and a significant
treatment x day interaction (F(19, 304)=2.34, p,0.01). Compared
to controls, vaccinated rats exhibited significantly fewer mean
infusions per session overall. By the end of the protocol (last three
sessions at FR3), KLH control rats self-administered 28.2566.689
infusions (mean6SEM), compared to only 6.56763.092 infusions
in vaccinated rats (t(16)=3.152, p,0.05), resulting in a significant
Vaccine Efficacy on Oxycodone Self-Administration and Brain mRNA
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0.460.2 mg/kg, respectively, t(10)=2.94, p,0.05). During the
entire study, control rats earned a mean total of 487.1692.8 SEM
infusions, while vaccinated rats earned a significantly lower mean
total of 194.2669.95 SEM infusions (t(16)=2.572, p,0.05),
resulting in a significant decrease in cumulative oxycodone intake
during the entire protocol (29.2365.566 SEM mg/kg vs
11.6564.197 SEM mg/kg, respectively, t(16)=2.572, p,0.05).
Finally, the proportion of rats meeting acquisition criteria in the
vaccine group was significantly lower compared to the control
group, respectively 30 and 87.5% (X
2
(1)=5.951, p,0.05).
3.2 Vaccination with OXY-KLH attenuates effects of
oxycodone self-administration on adenylate cyclase 5, c-
Fos, and early growth response 2 mRNA expression in rat
striatum
At 24 hours after the last oxycodone self-administration session,
we tested if vaccination affected the expression of several genes,
previously shown to be regulated by chronic opiate treatment,
including Adcy5, Egr2, c-Fos, Gai1, and Rgs9. To this end, rats
vaccinated with OXY-KLH were compared to KLH control rats
using qRT-PCR on RNA extracted from the NAc and DStr. The
effect of vaccination on gene expression in the NAc depended on
treatment (F(1,18)=12.77, p,0.05) and in the DStr, it depended on
an interaction between treatment and gene (F(4,72)=3.50, p,
0.05). Post hoc tests revealed that Fos and Egr2 mRNA levels were
significantly decreased (p,0.05) in the NAc of OXY-KLH rats
compared to control rats immunized with unconjugated KLH. In
the DStr, rats vaccinated with OXY-KLH showed significantly
(p,0.05) more Adcy5 and less Fos compared to the KLH control
group (Figure 2). These data suggest that oxycodone self-
administration decreases Adcy5 expression and increases Fos
and Egr2 expression, which is consistent with previous reports
showing similar regulation of these genes in response to chronic
morphine (Adcy5, Fos) [28] or heroin self-administration (Egr2,
Fos) [27].
To better understand the efficacy of vaccination in preventing
oxycodone-induced changes in gene expression, we tested if there
was any linear relationship between adenylate cyclase 5 mRNA
expression in the CPu and oxycodone-specific antibody titers,
mean infusions at FR3, total infusions and total oxycodone intake
in rats vaccinated with OXY-KLH or in all rats. No relationship
was found between Adcy5 mRNA expression and serum antibody
titers, self-administration performance or oxycodone intake in
vaccinated rats (not shown). However, among all rats, there was a
trend showing that Adcy5 mRNA expression was reduced in rats
with higher intake of oxycodone (Figure 3).
Discussion
The main findings of this study were that compared to a control
group immunized with the unconjugated carrier protein: 1)
vaccination with an oxycodone conjugate vaccine reduced the
proportion of rats that acquired oxycodone self-administration, 2)
vaccinated rats showed decreased mean infusions and total
oxycodone intake, and 3) 24 hours after 20 days of oxycodone
self-administration, vaccinated rats showed altered mRNA ex-
pression in the brain reward pathway. The finding that
vaccination blocked acquisition of oxycodone self-administration
is consistent with previous reports showing that active or passive
immunization can suppress nicotine, cocaine, heroin, or metham-
phetamine self-administration in rodents [7,9,11,26,30,31], and
extends this potential treatment approach to a class of abused
drugs that are of great current concern.
Prior studies showed that vaccination with OXY-KLH reduces
the early distribution of oxycodone and hydrocodone to the brain
and attenuates their nociceptive effects in mice and rats
[14,15,17,25]. Additionally, OXY-KLH showed equivalent pre-
clinical efficacy when administered by different routes or absorbed
on different adjuvants, and vaccine efficacy was also preserved
when the oxycodone-based 6OXY hapten was conjugated to the
tetanus toxoid and GMP-grade KLH carriers suitable for human
use [16]. The current study shows that OXY-KLH also markedly
reduces oxycodone reinforcement in a key animal model of
addiction. The total oxycodone dose self-administered per session
in control rats was within the range of oxycodone doses that are
commonly abused. The observed decrease in number of vacci-
nated rats acquiring oxycodone self-administration was similar to
that of a functional 6-acetlymorphine conjugate vaccine for
preventing acquisition of heroin self-administration [11,12].
There was no relationship between the oxycodone-specific
antibody titers and the observed reduction in mean infusions. This
observation has been previously reported with nicotine vaccines,
Figure 1. Vaccination attenuated acquisition of oxycodone self-administration in rats. Mean infusions of oxycodone (left panel) and mean
responses on the active and inactive levers (right panel) in rats immunized with OXY-KLH (n=10) or the unconjugated KLH carrier (n=8). The fixed
ratio (FR) is the number of active lever presses to deliver an intravenous infusion of 0.06 mg/kg oxycodone. All rats were tested in daily 120-minute
sessions. Data are expressed as mean6SEM. Statistical symbols: *p,0.01 compared to the OXY-KLH group.
doi:10.1371/journal.pone.0101807.g001
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antibody titers and mean nicotine infusions [26]. This is somewhat
surprising since it is known that immunization prevents drug
distribution to the brain through various pharmacokinetic
mechanisms. Possibly the sample size was too small to detect this
relationship or other sources of variability obscured it.
In the current study, during 120-minute intravenous self-
administration sessions at a FR3 schedule of reinforcement, the
total mean oxycodone intake in KLH control rats was
1.760.4 mg/kg (mean6SEM). In previous studies, vaccination
with OXY-KLH decreased the distribution of oxycodone to the
brain by 51% at 5 minutes after i.v. administration of 0.5 mg/kg
and by 74% at 30 minutes after s.c. administration of 2.25 mg/kg
in rats [14,15]. These doses, 0.5 mg/kg i.v. and 2.25 mg/kg s.c.,
produced respectively serum oxycodone concentrations between
82622 and 4286179 ng/ml (mean6SD) [14,15]. In healthy
subjects, oral doses of 10–15 mg of instant-release oxycodone
resulted in peak plasma concentrations of 15–20 ng/ml at 60–90
minutes after administration [32,33]. These data suggest that
OXY-KLH may be able to prevent distribution of clinically-
relevant doses of oxycodone.
In clinical studies of a nicotine vaccine, it has been shown that
vaccination reduced occupancy of b2-containing acetylcholine
nicotinic receptors in cortical structures of smokers receiving i.v.
bolus nicotine [34]. The present study shows that vaccination is
sufficient to prevent or alter drug-induced changes in mRNA
expression in subjects chronically exposed to oxycodone. Vacci-
nation prevented oxycodone-induced down-regulation of Adcy5
mRNA in the dorsal striatum, which occurs after chronic opioid
exposure [28]. In control rats immunized with the KLH carrier
alone, Adcy5 expression was reduced compared to rats vaccinated
with OXY-KLH suggesting that oxycodone self-administration, or
chronic exposure to oxycodone, down-regulates the expression of
Adcy5 in the dorsal striatum and that vaccination may prevent it.
In vaccinated rats, Egr2 and the immediate early gene c-Fos were
down-regulated compared to the KLH control group, suggesting
that vaccination may prevent increases of striatal Egr2 and Fos
expression in rats chronically exposed to opioids. These findings
indicate that vaccination prevented several drug-induced gene
expression changes commonly associated with opioid dependence
or chronic opioid exposure.
It is likely that the effects of OXY-KLH on mRNA expression
were the consequence of vaccination reducing the amount of
oxycodone that reached the brain during each self-administration
session. In support of this, there was a trend toward a relationship
between the amount of oxycodone self-administered and Adcy5
Table 1. Oxycodone-specific serum IgG antibody titers are expressed as x 10
3.
Treatment Titers Mean infusions (FR3) Total infusions (all sessions) Total drug intake (oxycodone, mg/kg)
KLH n/a 28674 8 7 693 3066
OXY-KLH 327664 763** 194670* 1264*
Data are expressed as mean6 SEM.
*p,0.05,
**p,0.01 compared to KLH control.
doi:10.1371/journal.pone.0101807.t001
Figure 2. Vaccination effects on oxycodone-induced brain gene expression in rat striatum. Brain gene expression was analyzed by qRT-
PCR at 24 hrs after the last oxycodone self-administration session. Panel A) caudate putamen, and panel B) nucleus accumbens. Data are expressed as
mean6SEM. Statistical symbols: *p,0.05, **p,0.01 compared to rats immunized with unconjugated KLH control vaccination group.
doi:10.1371/journal.pone.0101807.g002
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correlation found between the overall oxycodone intake during
self-administration and the mRNA expression of the neurotrans-
mitter Monoamine Oxidase A in mice [21]. The relationship
between oxycodone exposure during self-administration studies
and changes in brain gene expression in the striatum may have
also been mediated by oxycodone-induced neurochemical chang-
es. Since it has been shown that oxycodone self-administration
increases striatal dopamine release [22], it would be important to
test if vaccination against oxycodone has the ability of preventing
oxycodone-induced dopamine modulation within the mesolimbic
system.
In this study, no effect of vaccination was detected in the
dynorphin, KOR, Gai1, Gai2 and RGS9 mRNA expression in
either NAc or CPu. During exposure to opioids, Adcy5 activity in
the striatum is tightly regulated by RGS9 modifying the kinetics of
the Gai1 subunit and Gbc complex in opioid G-protein coupled
receptors [35]. It was therefore surprising to find no differences in
expression of Gai1, Gai2 and RGS9. The lack of changes in
mRNA expression may be due to the effect of chronic exposure to
oxycodone, which may mask effects otherwise detected after acute
opioid administration. Additionally, drug exposure may result in
alteration of enzymes, protein or activity rather than changes in
gene expression, which may explain why no oxycodone-induced
changes in Gai1, Gai2 and RGS9 expression were detected in this
study.
Overall, these data add to the evidence supporting the
preclinical efficacy of vaccination with OXY-KLH in blocking
oxycodone-induced addiction relevant behaviors, and support its
potential role in treating oxycodone abuse. Hydrocodone self-
administration was not studied, but OXY-KLH is effective in
reducing hydrocodone distribution to brain and antinociception in
rats, to the same degree as it blocks oxycodone effects. This study
also provides preliminary evidence of the potential ability of
vaccination to alter the effects of oxycodone on several key neural
mediators of opioid behavioral effects.
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